HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Berkowitz, R. L. Articles by Bussel, J. B. Search for Related Content PubMed PubMed Citation Articles by Berkowitz, R. L. Articles by Bussel, J. B.

Parallel Randomized Trials of Risk-Based Therapy for Fetal Alloimmune Thrombocytopenia

From the ¹Divison of Maternal–Fetal Medicine, Department of Obstetrics and Gynecology, Columbia College of Physicians and Surgeons, New York; ²Division of Pediatric Hematology/Oncology, the Children's Hospital at Mountefiore, Bronx, New York; ³Blood Center of Southeastern Wisconsin, Milwaukee, Wisconsin; ⁴Department of Pediatrics, Division of Hematology/Oncology, Weill Medical College of Cornell University, New York; and ⁵Department of Biostatistics, North Shore Medical Center, Manhasset, New York.

OBJECTIVE: Antenatal therapy with intravenous immunoglobulin (IVIG) and prednisone has been shown to improve fetal thrombocytopenia and reduce the incidence of intracranial hemorrhage in neonatal alloimmune thrombocytopenia. Optimization of this therapy for individual patients, however, has yet to be achieved.

METHODS: In these parallel, randomized, multicenter studies, 78 patients in 79 pregnancies were stratified to 2 different treatment arms based on the presence of a peripartum intracranial hemorrhage in a previously affected sibling and/or the initial fetal platelet count. Patients with a history of an antenatal intracranial hemorrhage in a prior pregnancy were excluded.

RESULTS: Forty women whose children from a previous birth had a peripartum intracranial hemorrhage or whose current fetus had an initial platelet count less than 20,000/mL³ were randomly assigned to receive IVIG plus prednisone or IVIG alone. The mean increase in fetal platelet counts in the following 3 to 8 weeks was 67,100/mL³ and 17,300/mL³, respectively (P < .001). Thirty-nine patients whose prior affected child did not have an intracranial hemorrhage and whose initial platelet count was more than 20,000/mL³ were randomly assigned to receive IVIG alone or prednisone alone. There were no significant differences, and 33 (85%) had birth platelet counts more than 50,000/mL³. There were 11 (6%) significant complications after a total of 175 fetal blood sampling procedures, 2 of which led to fetal or neonatal deaths.

CONCLUSION: The spectrum of disease severity of alloimmune thrombocytopenia is reflected in the initial fetal platelet count and response to therapy. Fetal blood sampling may be associated with significant fetal/neonatal morbidity and mortality. Empiric therapy sufficient to treat the most severely affected fetuses will overtreat others and is likely to be associated with additional maternal morbidity.

This article has been cited by other articles:

				C. Kaplan Neonatal alloimmune thrombocytopenia Haematologica, June 1, 2008; 93(6): 805 - 807. [Full Text] [PDF]

				R. L. Berkowitz, M. L. Lesser, J. G. McFarland, M. Wissert, A. Primiani, C. Hung, and J. B. Bussel Antepartum Treatment Without Early Cordocentesis for Standard-Risk Alloimmune Thrombocytopenia: A Randomized Controlled Trial Obstet. Gynecol., August 1, 2007; 110(2): 249 - 255. [Abstract] [Full Text] [PDF]